[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368556-105":59,"doc-detail-368556-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mutant-p53-specific-cd8tcr-therapy-combined-with-a-cd4tcr-prevents-relapse-of-cancer-and-outgrowth-of-micrometastases","Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases","","Relapse remains challenging in the treatment of metastatic cancers. More than 50% of human cancers harbor mutant p53 (mp53) as a cancer-specific target. Using the spontaneously metastasizing Ag104A model, the study identifies an autochthonous p53D256E neoantigen recognized by a CD8+ T cell-derived TCR (CD8TCR). Although CD8TCR therapy initially controls tumors, antigen-escape leads to relapse, which can be prevented by combining CD8TCR with a CD4TCR targeting mutant antigen presented by cancer stroma.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mutant-p53-specific-cd8tcr-therapy-combined-with-a-cd4tcr-prevents-relapse-of-cancer-and-outgrowth-of-micrometastases/368556/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mutant-p53-specific-cd8tcr-therapy-combined-with-a-cd4tcr-prevents-relapse-of-cancer-and-outgrowth-of-micrometastases/368556.png","ImageObject",300,407,{"name":92,"@type":93},"Fahsai","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is mutant p53 (mp53) considered a therapeutic target in metastatic cancers?","Question",{"text":112,"@type":113},"More than 50% of human cancers harbor mutant p53 as a cancer-specific target, enabling mp53-directed immune therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What neoantigen and TCR are identified in the Ag104A tumor model?",{"text":117,"@type":113},"The Ag104A model contains an autochthonous p53D256E mutation recognized by a CD8+ T cell-derived TCR (CD8TCR).",{"name":119,"@type":110,"acceptedAnswer":120},"How does combining CD8TCR therapy with a CD4TCR prevent relapse?",{"text":121,"@type":113},"No relapse occurs when CD8TCR is combined with a stroma-recognizing CD4TCR, preventing the relapse and macrometastasis development observed with monotherapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368556,1791047821,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","ONCOIMMUNOLOGY  \n2025, VOL. 14, NO. 1, 2514041 [https://doi.org/10.1080/2162402X.2025.2514041](https://doi.org/10.1080/2162402X.2025.2514041)  \nMutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases  \nVasiliki Anastasopouloua,b, Hans Schreiberc,d,e, Ching-En Leed, Kazuma Kiyotanif,g, Leo Hansmannh, Yusuke Nakamuraf,g, Matthias Leiseganga,b,c*, and Steven P. Wolfc,d*  \naInstitute of Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany; bGerman Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany; cDavid and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL, USA; dDepartment of Pathology, The University of Chicago, Chicago, IL, USA; eCommittees on Cancer Biology and Immunology and the Cancer Center, The University of Chicago, Chicago, IL, USA; fLaboratory of Immunogenomics, Center for Intractable Diseases and ImmunoGenomics (CiDIG), National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki-shi, Osaka, Japan; gProject for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan; hDepartment of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany  \nABSTRACT  \nRelapse remains challenging in the treatment of metastatic cancers. More than 50% of human cancers harbor mutant p53 (mp53) as a cancer-specific target. We present the spontaneously metastasizing tumor model Ag104A to advance mp53-specific T cell receptor engineered T cell therapy (TCR-therapy) . We identified in Ag104A an autochthonous p53D256E mutation as neoantigen recognized by a TCR isolated from CD8+ T cells (CD8TCR) . Cloning of the Ag104A cancer revealed mp53 expression in >99% of cancer cells. Targeting mp53 by CD8TCR-therapy was initially therapeutic, but tumors escaped as cancer cells with reduced or lack of antigen expression. Therefore, we determined whether escape could be prevented by combining the mp53-specific CD8TCR with a CD4+ T cell-derived TCR (CD4TCR) recognizing a mutant antigen presented on the stroma of the cancer. No relapse occurred when the mp53-specific CD8TCR was combined with the stroma-recognizing CD4TCR. The combination therapy also prevented the development of macrometastases from cancer cells that had already spread to the lung at the time ofTCR-therapy. Macrometastases were only observed after monotherapy. Thus, in a spontaneously metastatic model, tumor relapse and development of macrometastases can be prevented by combining a CD8TCR targeting an autochthonous p53-mutation with a mutation-specific CD4TCR recognizing tumor stroma.  \nARTICLE HISTORY  \nReceived 20 January 2025 Revised 17 April 2025 Accepted 25 May 2025  \nKEYWORDS  \nAdoptive cell transfer; metastatic tumor model; mutant p53; neoantigen; TCR-therapy  \nIntroduction  \nCancer is caused by mutations in the genome. Many of these mutations are cancer-specific somatic point mutations encoded by non-synonymous single nucleotide variants (nsSNVs) . They cause single amino acid substitutions and are the basis of unique tumor-specific antigens, 1 now often referred to as neoantigens. Indeed, extensive studies inhuman cancers have shown that about 99% of these neoantigenic determinants are not shared between patients and are  \ntherefore appropriately being referred to as “unique”.2  \nCancer-specific mutations in the tumor suppressor gene TP53 are almost universal in human and murine malignancies. Therefore, various approaches to p53-targeted therapies, including immunological ones, have been developed over the past several decades.3 Changes in p53 are mostly the results of point mutations that occur in evolutionarily conserved codonsin certain regions of the gene, also referred to as mutational hotspots.4 These point mutations are highly variable between patients, and therapeutic reagents must be tailored to the  \nparticular neoantigenic","cbCaitnErQhT3W4c","https://ap.wps.com/l/cbCaitnErQhT3W4c","pdf",4471881,14,"English","# Abstract\n## Target identification in the Ag104A model\n## CD8TCR monotherapy escape and relapse\n## Combination therapy with CD4TCR and outcome prevention","[{\"question\":\"Why is mutant p53 (mp53) considered a therapeutic target in metastatic cancers?\",\"answer\":\"More than 50% of human cancers harbor mutant p53 as a cancer-specific target, enabling mp53-directed immune therapies.\"},{\"question\":\"What neoantigen and TCR are identified in the Ag104A tumor model?\",\"answer\":\"The Ag104A model contains an autochthonous p53D256E mutation recognized by a CD8+ T cell-derived TCR (CD8TCR).\"},{\"question\":\"How does combining CD8TCR therapy with a CD4TCR prevent relapse?\",\"answer\":\"No relapse occurs when CD8TCR is combined with a stroma-recognizing CD4TCR, preventing the relapse and macrometastasis development observed with monotherapy.\"}]","Mutant p53-specific CD8TCR-therapy combined with a CD4TCR prevents relapse of cancer and outgrowth of micrometastases | PDF",1790177483,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82a6899846f8c6497f0ba5519d6c35a3.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5793c38d14ce0c361a35b5543566d284.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/edc5397cce5f2a9332b43c92d3f8b4b8.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebfafd883daffae672e7f739fccd190d.webp",980,1306]